

**REMARKS**

Claims 1-29 are presented in this application. In this amendment, claims 7, 9, 10-11, 14-15, 19-23, and 27 have been amended, and claims 24-26 and 28 have been cancelled. Claims 7, 9, 10-11, 14-15, 19-23, and 27 have been amended to place them in form appropriate to US practice and to remove multiple dependencies for the purpose of reducing fees. Basis for the word "solvate" in the claims is found in the application at page 9, line 39.


Applicants have amended the specification for purposes of adding the priority information. Further, appropriate headings have been inserted on accordance to 37 CFR 1.77. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

  
Bonnie L. Deppenbrock  
Attorney for Applicant  
Registration No. 28,209

Date: 12 October 2005  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-1577  
Facsimile: 919-483-7988